These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Moderna is nearing approval for its mRNA-1010 flu vaccine and has additional catalysts ahead, including a norovirus launch and multiple data readouts over the next two years. Krystal Biotech continues to grow from Vyjuvek, with an 11-quarter streak of positive EPS and further pipeline/readout potential, while AMD is up 129% YTD and is positioned to benefit from AI-driven demand in server CPUs. The piece is broadly bullish on all three names, but it is primarily an opinion article rather than a new company-specific event.

Analysis

The common thread is not “three good businesses,” but three different forms of duration: Moderna is a binary pipeline re-rate, Krystal is a compounding commercial-story extension, and AMD is a secular share-gain plus margin expansion story. The market is rewarding visible catalysts more than distant optionality, which means each name is vulnerable to different kinds of disappointment: clinical timing for MRNA, saturation/mix pressure for KRYS, and valuation compression if AI capex shifts from “build” to “harvest” before AMD’s accelerator share meaningfully inflects.

The second-order winner set is broader than the article implies. If AMD keeps taking CPU share, Intel’s erosion becomes a procurement and ecosystem issue, not just a revenue issue; that can pressure adjacent server platforms, board vendors, and OEM pricing discipline. In biotech, success at KRYS reinforces investor willingness to fund single-asset rare-disease commercial plays, but it also raises the bar for what constitutes “platform value” versus one-drug momentum; names without clear geographic expansion or follow-on pipeline may lag.

The contrarian read is that MRNA’s upside is being underwritten by too many future shots on goal, while KRYS and AMD may already be pricing in smooth execution. For MRNA, the market can tolerate pipeline volatility until the first major regulatory delay, but once timelines slip by even one quarter, multiple compression can be abrupt. For AMD, the key risk is not share loss to Nvidia in the near term; it is that incremental AI profit pools remain concentrated in GPUs, leaving CPU TAM growth real but slower to monetize than the stock’s recent move suggests.

Key Decisions for Investors

• Long AMD / short INTC for 3-6 months: express continued server CPU share migration; use a 1:1 notional pair and target a 15-20% relative spread if AMD execution stays intact.
• Buy MRNA on pullbacks only, or structure a call spread into the next regulatory/data catalyst: upside is meaningful if one approval hits, but time decay is punitive if timelines slip; prefer limited-risk optionality over spot.
• Trim KRYS into strength and re-enter on any post-data consolidation: the stock likely continues compounding, but after a strong run the cleanest risk/reward is waiting for a 10-15% reset rather than chasing.
• For AMD, consider taking partial profits or hedging with a short-dated call overwrite: the secular thesis remains intact, but sentiment is vulnerable to any guide-down in AI-related demand timing over the next 1-2 quarters.
• Watch INTC/AMD relative performance as a leading indicator of server refresh budgets; if INTC stabilizes unexpectedly, reassess the pair trade quickly because the market is pricing in a longer share-loss runway than a single quarter can confirm.